Mangalam Drugs & Organics Ltdte Share Price & Stock Analysis

Mangalam Drugs & Organics Ltdte (BSE: 532637) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹46 Cr, it ranks #3,839 by market cap among the 6,197 Indian listed companies on FinBizNet, and #75 of 86 in Medicinal Chemicals and Botanical Products. At ₹29.20 (as of 16 Nov 2026), the share price is 53.3% below its 52-week high of ₹62.50 and 28.1% above its 52-week low of ₹22.80. The share price is down 54.2% over one year and up 5.2% over three months.

Key Metrics

Current Price₹29.20
Market Cap₹46 Cr
BSE Code532637
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E RatioNot meaningful (loss)
Return on Equity-35.23%
Return on Assets-5.96%
52-Week Range₹22.80 – ₹62.50
1-Year Price Change-54.2%
3-Month Price Change+5.2%
Beta (1Y)0.36
Dividend Yield0.00%
HeadquartersMumbai, Maharashtra
Websitewww.mangalamdrugs.com

Latest Quarterly Results — Q2 FY27

Revenue₹79 Cr
Net Profit₹-7 Cr
Net Margin-9.1%
EPS (Basic)₹-4.55
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Mangalam Drugs & Organics Ltdte Quarterly Revenue and Profit Trend

Mangalam Drugs & Organics Ltdte reported revenue of ₹79 Cr in Q2 FY27, up 60.3% from ₹50 Cr in Q2 FY26 and up 39.0% from ₹57 Cr in Q1 FY27. It posted a net loss of ₹7 Cr for the quarter, against a net loss of ₹7 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹50 Cr (Q2 FY26) to ₹79 Cr (Q2 FY27). The company reported a net loss in 6 of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹79 Cr−₹7 Cr−9.1%
Q1 FY27₹57 Cr−₹8 Cr−13.4%
Q4 FY26₹67 Cr−₹13 Cr−19.9%
Q3 FY26₹58 Cr−₹10 Cr−16.8%
Q2 FY26₹50 Cr−₹7 Cr−14.8%
Q1 FY26₹57 Cr−₹14 Cr−24.1%
Q4 FY25₹73 Cr₹0 Cr0.1%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 35.65% of Mangalam Drugs & Organics Ltdte's shares as of Sept 2026, against 50.30% in Sept 2025 (−14.65 percentage points). Delivery averaged 76.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Mangalam Drugs & Organics Ltdte

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals comp

Products and Services

1. Manufacturing of Bulk Drugs-This segment manufactures and sells drugs, medicines, and allied products. 2. Chemicals & Others-0 3. Segment Adjustment-This segment manufactures organic chemicals, prefumery/specialty chemicals, disperse dye intermediates, and dye products. 4. Corporate-0

Business Segments

1. Manufacturing of Bulk Drugs-100%

Mangalam Drugs & Organics Ltdte vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Mangalam Drugs & Organics Ltdte₹46 Crn/m-35.23%₹79 Cr-54.2%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Mangalam Drugs & Organics Ltdte?

Mangalam Drugs & Organics Ltdte is trading at ₹29.20, with a market capitalisation of ₹46 Cr.

Which sector does Mangalam Drugs & Organics Ltdte belong to?

Mangalam Drugs & Organics Ltdte operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Mangalam Drugs & Organics Ltdte?

Mangalam Drugs & Organics Ltdte has a return on equity of -35.23%.

What is the stock symbol of Mangalam Drugs & Organics Ltdte?

Mangalam Drugs & Organics Ltdte is listed on the BSE under the scrip code 532637.

How has Mangalam Drugs & Organics Ltdte's share price moved over the past year?

Mangalam Drugs & Organics Ltdte's share price is down 54.2% over one year and up 5.2% over three months. Its 52-week range is ₹22.80 to ₹62.50.

What were Mangalam Drugs & Organics Ltdte's latest quarterly results?

In Q2 FY27, Mangalam Drugs & Organics Ltdte reported revenue of ₹79 Cr and net profit of ₹-7 Cr, with basic EPS of ₹-4.55 (consolidated, parsed from the company's exchange filing).

How have Mangalam Drugs & Organics Ltdte's revenue and profit changed over the past year?

Mangalam Drugs & Organics Ltdte reported revenue of ₹79 Cr in Q2 FY27, up 60.3% from ₹50 Cr in Q2 FY26 and up 39.0% from ₹57 Cr in Q1 FY27.

What is the promoter holding in Mangalam Drugs & Organics Ltdte?

Promoters held 35.65% of Mangalam Drugs & Organics Ltdte's shares as of Sept 2026, against 50.30% in Sept 2025 (−14.65 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.